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Background: The association between obesity and Barrett’s esophagus (BE) in the Japanese population remains
unclear. The prevalence of BE and its associated risk factors was examined.
Methods: A cross-sectional study of 1581 consecutive individuals who underwent upper gastrointestinal
endoscopy was conducted. The prevalence of endoscopically suspected BE (ESBE) was evaluated. Obesity was
evaluated by body mass index (BMI, ≥ 25 kg/m2) and waist circumference (WC) (males, ≥ 85 cm; females, ≥ 90 cm).
Because endoscopic diagnosis of ultra-short ESBE (<1 cm in extent) is difficult and highly unreliable, this type of
ESBE was excluded from the study.
Results: In proton pump inhibitor (PPI) non-users, the prevalence of ESBE≥ 1 cm was 5.6%. In univariate analysis, male
sex and reflux esophagitis (RE) were significantly associated with BE, but BMI, WC, and reflux symptoms were not. In
multivariate logistic regression analysis, only RE (odds ratio [OR] = 3.48, 95% confidence interval [CI] 1.89-6.41, p < 0.0001)
was an independent risk factor for BE; obesity and the other factors were not. In contrast, RE (OR 5.67, p = 0.0004) and
large WC (OR 5.09, p = 0.0005) were significant risk factors for ESBE≥ 1 cm in PPI users. Only male sex, but not obesity or
the other risk factors, was associated with an increased risk of RE in patients not taking PPIs.
Conclusions: RE, but not obesity, may have an independent association with the risk of ESBE in the Japanese
population. Furthermore, obesity measures were not independent risks for RE. Interestingly, PPI-refractory RE and large
WC were risk factors for ESBE ≥1 cm in patients taking PPIs.
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The main risk for Barrett’s esophagus (BE) is considered
to be gastroesophageal reflux disease (GERD) [1-4]. El-
Serag reported that the incidence GERD has increased
significantly in each of the last two decades in North
America and Europe but not Asia [5]. However, the inci-
dence of GERD is increasing in Japan as well as in the
West [6]. These results suggest that the prevalence of
GERD-associated BE will increase in Japan over the next
few decades.* Correspondence: watarij@hyo-med.ac.jp
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reproduction in any medium, provided the orThere is strong evidence from epidemiological studies
conducted among Western populations that total obesity,
as measured by body mass index (BMI), is associated with
GERD symptoms, reflux esophagitis (RE) and esophageal
adenocarcinoma [7,8]. Furthermore, these studies have
shown that waist circumference (WC) and the waist-to
-hip ratio (WHR), both of which measure abdominal fat,
are risk factors for BE, independent of BMI [9,10].
In contrast, few studies have investigated the associ-
ation between obesity and BE in a Japanese population.
RE studies conducted in Japan have found a positive as-
sociation between high BMI and RE [11,12], and RE is
thought to be associated with the development of BE in
the Japanese population [13,14]. In their retrospectiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tween visceral obesity and BE in Japanese patients with
non-alcoholic fatty liver disease, with visceral obesity be-
ing defined using visceral adipose tissue (VAT) measure-
ments on abdominal computed tomographic images, but
the strength of the risk of BE was very weak (odds ratio
[OR], 1.0074; 95% confidence interval [CI], 1.0001-
1.0147, p = 0.0472) [15]. Previous reports from Japan on
the association between obesity and RE or BE have been
limited to retrospective studies [13,15]. Therefore, it re-
mains controversial whether obesity is actually an inde-
pendent risk factor for BE in Japanese subjects.
In most of the BE cases identified in Japan, the lesions
were very short, i.e., < 1 cm in length. Such cases are clas-
sified as ultra-short BE, although the diagnosis of this dis-
ease entity is difficult and highly unreliable [16-18]. One
possible reason for the difficulty may be the use of differ-
ent definitions of the gastroesophageal junction (GEJ), i.e.,
the distal end of the esophageal palisade vessels versus the
proximal margin of the gastric folds [16,19,20]. As defined
in the West, BE diagnosis requires histological confirm-
ation of the specialized intestinal metaplasia (SIM). Thus,
cases without histological confirmation of SIM are defined
as endoscopically suspected BE (ESBE) in the US but are
not regarded as BE [21]. Furthermore, the previous studies
have included patients who were taking proton pump in-
hibitors (PPIs), which may induce the regression and
normalization of BE [14,22,23]. Thus, the associations be-
tween obesity and BE should be investigated separately in
patients taking and those not taking PPIs.
A recent study by Kramer et al. found no associations
between BMI, WHR and short-segment BE, but a strong
and statistically significant association between WHR
and long-segment BE in the US [24]. In the current
study, we focused on short-segment BE, and excluded
ultra-short BE, and analyzed the association between this
disease entity and obesity separately in patients taking
and those not taking PPIs in Japan.
Methods
Patients
A hospital/clinic-based, cross-sectional, pilot study
assessing the association between obesity and the develop-
ment of BE was performed. Between November 2011 and
June 2012, 1581 consecutive patients who underwent upper
endoscopy at the Gastroenterology Division of Hyogo Col-
lege of Medicine Hospital (n = 1114), one affiliated hospital
(n = 327), and one clinic (n = 140) were enrolled in this
study. Most patients were outpatients, and patients who
had previously undergone upper gastrointestinal tract sur-
gery, who had previously undergone endoscopy during this
period, and those who were followed in the surveillance
registry of BE in our department were excluded. At the af-
filiated hospital and the clinic, transnasal endoscopy withan ultrathin endoscope was performed only for medical
check-up, while at our college hospital endoscopy was
performed for various reasons, such as GERD symptoms
(n = 200, 18.0%), detailed examination of gastric cancer or
neoplasms (n = 78, 7.0%), follow-up study after endoscopic
treatment for dysplasia and/or cancer (n = 36, 3.2%), and
other reasons, including screening, follow-up for peptic ul-
cers, and so on. A standardized questionnaire was used to
obtain a history from each subject regarding GERD symp-
toms, smoking and alcohol habits prior to endoscopy.
Whether or not subjects were taking PPIs was determined
by self-report and a review of the medical prescriptions in
our database. The Ethics Committee of Hyogo College of
Medicine and the affiliated hospital and clinic approved this
study. Written, informed consent was obtained from all pa-
tients prior to this study.
Endoscopy protocol
In Japan, the GEJ is defined as the distal limit of the
lower esophageal palisade vessels [21], but in the West
the GEJ is defined as the proximal margin or upper end
of the gastric folds (Prague C&M criteria) [16]. In the
present study, ESBE was diagnosed endoscopically as
columnar-lined epithelium between the lower end of the
palisade vessels of the lower esophagus and the squamo-
columnar junction. However, if the palisade vessels could
not be visualized clearly, the upper end of the gastric
folds was regarded as the GEJ. When the ESBE length
was considered to be 1 cm or more, the length was mea-
sured in comparison to the length of the endoscope. In
contrast, when the length was considered to be < 1.0 cm,
the ESBE length was judged in comparison to the biopsy
forceps (the open forceps were about 7 mm in diameter;
Radial Jaw™ 4: Boston Scientific Corporation, Natick,
MA). If possible, at least one biopsy specimen was
obtained from ESBE, > 5 mm in extent, in order to con-
firm the presence of SIM on histology. Atrophic gastritis
was classified into 2 types according to the Kimura and
Takemoto classification [25]: the closed type, as mild
atrophic gastritis (C 1–3), and the open type, as severe
atrophic gastritis (O 1–3). RE was diagnosed based on
the Los Angeles (LA) classification [26], and individuals
with LA classification grade A or more were considered
positive for RE. These endoscopic data were prospect-
ively collected.
Measures of adiposity
Prior to endoscopy, we performed the following body
measurements of the subjects. BMI was calculated as
weight divided by the square of height (kg/m2). “Obes-
ity” was defined as BMI ≥ 25.0 kg/m2, based on the cri-
teria of the Japanese Society of Obesity [27]. A large WC
based on the Japanese criteria (≥ 85 cm for men, ≥
90 cm for women) was defined as an abnormal WC [28].
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males and ≥ 0.85 for females, according to the definition
of Ilanne-Parikka et al. [29].
Symptoms and habits
GERD symptoms were defined as the presence of either
heartburn or acid regurgitation at least once weekly. Also,
the presence of a current alcohol (active consumption of
any amount of alcohol) or cigarette (active smoking of any
number of cigarettes) habit was determined by interview
prior to the study. A PPI user was regarded as a patient
who had continuously taken a PPI such as omeprazole
(20 mg/day), lansoprazole (15 or 30 mg/day), rabeprazole
(10 or 20 mg/day), or esomeprazole (20 mg/day) once a
day beginning at least 2 months before this study.
Statistical analysis
The data were assessed by the Mann–Whitney U-test
for patients’ age and adiposity measures, and the chi-
square test or Fisher’s exact test for the other variables
between the two groups. Statistical significance was de-
fined as a p value < 0.05. Odds ratios (ORs) and the cor-
responding 95% confidence intervals (CIs) for risk
factors for ESBE and RE were calculated using StatView
Version 5.0 for Macintosh (SAS Institute Inc., Cary,
NC). We included all factors with p < 0.10 in unadjusted
models in the multiple logistic regression model. Those
factors with p > 0.05 in backwards stepwise regression
were dropped from the final model.
Results
Patient characteristics
A total of 1581 individuals (921 men, 660 women) were
enrolled in this study. Their mean age was 58.9 ±
14.7 years (range: 18 to 92 years). Of these, 1214 patientsTable 1 Clinical characteristics of the patients with endoscop
PPI non-use
Controls ESBE ≥ 1 cm
Number 840 (69.2) 68 (5.6)
SIM - 19/49 (38.8
Patients profile
Age, y 56.2 ± 14.8 58.3 ± 13.6
Male sex 464 (55.2) 47 (69.1)
Alcohol drinking 244 (29.0) 20 (29.4)
Current smoking 173 (20.6) 14 (20.6)
GERD symptoms 126 (15.0) 12 (17.6)
Endoscopic findings
Reflux esophagitis 68 (8.1) 17 (25.0)
Gastric atrophy (Open-type) 158 (18.8) 16 (23.5)
PPI proton pump inhibitor, ESBE endoscopically suspected Barrett’s esophagus, SIM
NS not significant.(76.8%) were not taking PPIs and, of these, 840 (69.2%)
showed no evidence of ESBE on endoscopy and thus
constituted our control group. On the other hand, the
remaining 367 patients were regular PPI users, of whom
256 (69.8%) did not show ESBE and the remaining 111
(30.2%) had ESBE.
Among patients who were not taking PPIs (n = 1214),
the prevalence of ESBE was 30.8% (374 cases): 25.2% (n =
306) for ultra-short ESBE, 5.4% (n = 65) for ESBE of ≥1 cm
but <3 cm, and only 0.2% (n = 3) for long-segment ESBE
(LSBE, ESBE ≥ 3 cm). On the other hand, that of ESBE
among patients taking PPIs (367 cases) was 30.3%: 24.0%
(n = 88) for ultra-short-segment ESBE, 5.2% (n = 19) for
ESBE of ≥1 cm but <3 cm, and 1.1% (n = 4) for long-
segment ESBE.
Factors predicting development of ESBE ≥ 1 cm and RE
Because endoscopic diagnosis of ultra-short ESBE is dif-
ficult and highly unreliable, as mentioned above, patients
with ultra-short ESBE were excluded from this
evaluation.
As shown in Table 1, SIM was identified in patients
with ESBE ≥ 1 cm (38.8%) among PPI non-users in
whom a biopsy could be obtained, but did not differ
from the frequency of SIM (44.4%) among regular PPI
users who underwent biopsy. In patients not taking PPIs,
there was no significant difference in age between the
controls and the ESBE group. The percentage of males
was significantly higher among patients with ESBE ≥
1 cm than among controls (p = 0.03). RE was detected
with significantly greater frequency in patients with
ESBE ≥ 1 cm than among controls (p < 0.0001), both for
patients taking and those not taking PPIs.
Among both patients taking and those not taking PPIs,
all adiposity measures including BMI, WC, and WHR inically suspected Barrett’s esophagus ≥ 1 cm
rs PPI users
P Controls ESBE ≥ 1 cm P
- 256 (69.8) 23 (6.3) -
) - - 8/18 (44.4) -
0.31 63.5 ± 15.3 67.5 ± 12.4 0.26
0.03 129 (50.4) 14 (60.9) 0.34
0.95 54 (21.1) 8 (34.8) 0.13
0.99 34 (13.3) 3 (13.0) > 0.99
0.56 74 (28.9) 9 (39.1) 0.30
<0.0001 22 (8.6) 8 (34.8) 0.0001
0.34 96 (37.5) 6 (26.1) 0.28
specialized intestinal metaplasia, GERD gastroesophageal reflux disease,
Table 2 Distributions of BMI, WC and WHR among cases and controls
A. Patients not taking PPIs
Adiposity measures Controls (%) ESBE ≥ 1 cm (%) P value
BMI, kg/m2 21.8 ± 3.5 (17.2)* 22.9 ± 2.64 (30.4)* 0.11
WC, cm 80.3 ± 10.8 (23.4)** 82.7 ± 8.68 (60.9)** <0.0001
WHR 0.87 ± 0.08 (49.6)† 0.90 ± 0.04 (42.9)† 0.55
B. Patients regularly taking PPIs
Adiposity measures Controls (%) ESBE ≥ 1 cm (%) P value
BMI, kg/m2 22.4 ± 3.5 (19.5)* 22.3 ± 3.3 (19.1)* 0.94
WC, cm 80.8 ± 10.2 (29.8)** 81.5 ± 10.1 (36.8)** 0.27
WHR 0.88 ± 0.08 (46.7)† 0.88 ± 0.06 (42.3)† 0.54
BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, PPI proton pump inhibitor.
ESBE endoscopically suspected Barrett’s esophagus.
P values indicate the comparison in the prevalence between controls and ESBE ≥ 1 cm.
* The prevalence indicates body mass index ≥ 25 kg/m2.
** The prevalence indicates a large waist circumference defined as ≥ 85 cm for males and ≥ 90 cm for females.
† The prevalence indicates a large waist-to-hip ratio defined as ≥ 0.9 for males and ≥ 0.85 for females.
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ent from those among controls (Table 2). However, the
prevalence of large WC was significantly higher in pa-
tients with BE ≥1 cm than in the controls (p < 0.0001)
among patients regularly taking PPIs, but not among
those not taking PPIs.
When analyzing the strength of the association between
obesity and ESBE development on multivariate logistic re-
gression analysis, RE was an independent risk factor for
ESBE ≥ 1 cm in both patients who were not taking PPIs
(OR = 3.48, 95% CI = 1.89-6.41, p < 0.0001) and those who
were regularly taking PPIs (OR = 5.67, 95% CI = 2.17-
14.86, p = 0.0004) (Table 3). Intriguingly, a large WC was a
significant risk factor for BE ≥ 1 cm (OR= 5.09, 95%CI =
2.04-12.72, p = 0.0005) only among regular PPI users.
Next, the relationship between RE and the patient
characteristics was investigated in patients not taking
PPIs. Male sex (p < 0.0001) and alcohol drinking (p =
0.049) were significantly associated with the develop-
ment of RE (data not shown), whereas gastric atrophyTable 3 Predictors of the development of endoscopically susp
A. Patients not taking proton pump inhibitors
Univariate
OR 95% CI
Male sex 1.81 1.07–3.09
Reflux esophagitis 3.78 2.07–6.91
B. Patients regularly taking proton pump inhibitors
Univariate
OR 95% CI
Reflux esophagitis 5.67 2.17–14.86
Large waist circumference * 5.08 2.10–12.33
OR odds ratio, CI confidence interval.
* Large waist circumference is defined as ≥ 85 cm for males and ≥ 90 cm for femalesignificantly reduced the development (p = 0.02). In
keeping with the findings from previous studies in the
West [7,8] and Japan [11,12] in which RE was signifi-
cantly associated with obesity, all adiposity measures in
the present study, i.e., BMI, WC, and WHR, were signifi-
cantly greater in patients with RE than in those without
(p < 0.0001, p < 0.0001, and p = 0.0006, respectively)
(Table 4). Moreover, all obesity indices were associated
with RE (p = 0.001, p = 0.0003, and p = 0.02, respectively).
In the multivariate analyses, however, only male sex, but
none of the obesity measures, was a risk factor for RE
(Table 5). Among patients taking PPIs, only GERD
symptoms were significantly associated with RE develop-
ment (p = 0.004, data not shown).
Discussion
A recent study in the US reported that high WHR, but
not BMI, was associated with a significant increase in
the risk of LSBE but not short-segment BE in white men
[24]. The present study is the first cross-sectional studyected Barrett’s esophagus
Multivariate
P value OR 95% CI P value
0.03 1.61 0.94–2.77 0.08
<0.0001 3.48 1.89–6.41 <0.0001
Multivariate
P value OR 95% CI P value
0.0004 5.67 2.17–14.86 0.0004
0.0003 5.09 2.04–12.72 0.0005
s.
Table 4 Relationship between reflux esophagitis and
obesity in patients not taking PPIs
Reflux esophagitis
Adiposity measures Positive Negative P value
BMI, kg/m2 23.6 ± 3.6 22.4 ± 3.4 <0.0001
WC, cm 84.5 ± 10.0 80.8 ± 10.1 <0.0001
WHR 0.90 ± 0.07 0.87 ± 0.08 0.0006
PPI proton pump inhibitor, BMI body mass index, WC waist circumference,
WHR waist-to-hip ratio.
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the association between obesity and the risk of ESBE, es-
pecially short-segment ESBE, in a Japanese population.
The pathognomonic point of this study is that the risk
factors for ESBE ≥ 1 cm, excluding ultra-short ESBE for
which endoscopic diagnosis is highly unreliable, were in-
vestigated separately in subjects taking and those not
taking PPIs in order to exclude the possibility of a drug
affecting the pathophysiology of BE.
The natural history of GERD, including RE, is incom-
pletely understood because very few well-designed prospect-
ive studies and endoscopic studies in general populations
have been performed [30]. In the current study, RE was a
significant risk factor for ESBE development. In two retro-
spective studies from Japan, RE was shown to be associated
with ESBE [13,14] and also with the progression of ESBE
using a multivariate model [13]. Therefore, the present
findings support these previous results from Japan. How-
ever, these studies unfortunately included ultra-short ESBE.
According to the previous reports [14,22,23], PPI adminis-
tration might heal RE and induce short BE to regress. Of
367 patients who were regularly taking PPIs, 33 subjects
(9.0%) showed RE in the present study (data not shown). It
has been reported that the proportion of PPI-refractory RE
patients is approximately 7–15% [31], a finding that is con-
sistent with the present result. Furthermore, the incidence
of PPI treatment-resistant RE was significantly higher in pa-
tients with ESBE ≥ 1 cm (34.8%) than in those with ultra-Table 5 Predictors for the development of reflux esophagitis
Univariate
OR 95% CI
Male sex 2.57 1.68–3.93
Alcohol drinking 1.47 1.01–2.15
Gastric atrophy (Open-type) 0.54 0.31–0.93
BMI (25≤) 1.95 1.31–2.92
WC * 1.98 1.37–2.87
WHR ** 1.70 1.09–2.66
PPI proton pump inhibitor, OR odds ratio, CI confidence interval, BMI body mass ind
* Large waist circumference is defined as 85 cm ≤ for males and 90 cm ≤ for female
** Large waist-hip ratio is defined as ≥ 0.9 for males and ≥ 0.85 for females.short ESBE (3.4%, 3 of 88) (p = 0.0001, data not shown).
These results indicate that PPI-refractory RE may be
strongly associated with an increasing risk of developing
ESBE ≥ 1 cm.
In the current study, all adiposity measures were sig-
nificantly associated with RE, whereas obesity was not a
risk factor for increased BE. Observational studies from
Asia have reported a consistent association between WC
or VAT and RE [32,33]. Two studies of RE in a Japanese
population showed that abdominal obesity may be an
important risk factor for RE in males, but not in females
[34,35], but another report did not show this association
[36], which has led to some controversy about the asso-
ciation between obesity and RE. The present study
clearly demonstrated that RE was an independent risk
factor for ESBE, while obesity was not a risk factor for
RE. Only male sex was an independent risk factor for RE
development. As reported previously from Western
countries, differences in body fat distribution, rather
than simple obesity as measured by the BMI, may cause
GERD or BE, with abdominal fat deposition leading to
an increase in intra-abdominal pressure and GERD.
Corley et al. also noted that WC may predict the risk of
BE or esophageal adenocarcinoma better than BMI [9].
It is also true that there are differences in the demo-
graphic distribution of BE by race and ethnicity [37].
The difference in the association between obesity and
RE or BE might be explained, at least in part, by ethnic
differences in the obesity pattern, especially the pattern
of visceral adipose tissue deposition [15]. Intriguingly, in
patients who are taking PPIs, large WC was a risk factor
for ESBE ≥ 1 cm but not for ultra-short ESBE (data not
shown), although the reason for this finding is unclear.
The differences in risk factors between ultra-short and
BE ≥ 1 cm indicate that the pathophysiologies of these
two conditions may be different [38]. One possible
mechanism for the development of ESBE ≥ 1 cm in Japa-
nese subjects may be that visceral obesity as measured
by WC is associated with severe esophageal acidin patients who are not taking PPIs
Multivariate
P value OR 95% CI P value
< 0.0001 2.22 1.25–3.92 0.006
0.05 1.10 0.68–1.80 0.70
0.03 0.57 0.32–1.03 0.06
0.001 1.51 0.85–2.70 0.16
0.0003 1.04 0.56–1.94 0.89
0.02 1.57 0.92–2.67 0.10
ex, WC waist circumference, WHR waist-to-hip ratio.
s.
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treatment alone. Therefore, 24-hour esophageal pH
monitoring will be needed to clarify the mechanism in
such patients.
Male sex was not a significant risk factor for ESBE
with or without PPIs (OR 1.61, 95% CI = 0.94-2.77, p =
0.08) in this study, although it was associated with an in-
creased risk of RE development. Male sex has been
reported to be an important predictive factor for BE
[10,37]. Generally, the appropriate WC in females differs
from that in males because there is a difference in the
preferential accumulation of VAT between females and
males [39,40]. Thus, the risk factors for BE development
may be different between females and males. However,
no association between obesity and RE or ESBE was
found in either females or males in the present study
(data not shown). Further investigation may be required
using a larger series of samples to determine the associ-
ation between gender and BE.
There was no significant difference in the prevalence
of ESBE, including ultra-short ESBE, between patients
taking PPIs (30.2%, 111 of 367) and those not taking
PPIs (30.8%, 374 of 1214). The prevalence rates of endo-
scopically suspected LSBE were only 1.1% and 0.2% in
patients taking PPIs and those not taking PPIs, respect-
ively; therefore, the remaining cases were mostly short-
segment ESBE, especially ultra-short ESBE < 1 cm. These
findings are consistent with reports from Japan and Asia,
in which SSBE was shown to be more common and
LSBE more rare than in Western countries [41,42]. It
remains unclear why the prevalence of LSBE is different
between Japan and the West. Some possible reasons for
this difference include differences in genetic suscep-
tibility, genetic polymorphisms, diet or other clinical/
nutritional factors, and environmental influences (socio-
economic status) [43], along with differences in the
definition of the BE and GEJ.
The frequency of SIM increased with longer BE, a
finding that is consistent with recent reports [44,45]. In
our study, biopsy sampling was not done based on the
Seattle biopsy protocol, which is a widely accepted
method for performing surveillance biopsies [46], and
this omission presumably increased the chance of bias
inclusion. However, SIM was detected in 38.8% (19 of
49) of patients with ESBE ≥ 1 cm who were not taking
PPIs, even in those with ultra-short BE (20.2%, 23 of
114), and this prevalence was higher compared to the
finding of Westerhoff et al. [44]. It may be problematic
to distinguish metaplasia of the gastric cardia from
metaplasia of the BE and GEJ [10]. We previously
reported that SIM obtained from SSBE, mostly ultra-
short BE, was distinct from metaplasia in the cardia and
the antrum from a practical molecular pathology stand-
point [47]. More recently, it was reported that palisadevessels are a specific, original, and useful histologic
marker of tissue originating from the esophagus [48],
thus supporting the Japanese criteria in which the distal
end of the esophageal palisade vessels is considered the
GEJ. Taking the findings of these reports into consider-
ation, we believe that ESBE with palisade vessels as
investigated in the present study should actually be diag-
nosed as BE irrespective of the presence or absence of
SIM based on the Japanese [49] or British criteria [50].
The present study had several potential limitations. A
possible weakness is that only ESBE without histological
confirmation of SIM was evaluated, in contrast with the
American criteria [21]. Although we examined the effect
of obesity on the risk of BE with SIM, there was no sig-
nificant association between them because of the limited
number of cases of BE ≥ 1 cm with SIM (n = 19). Further
study will be needed to accurately clarify this association
in a Japanese population as well as in the West. Second,
this study was a hospital/clinic-based study, so the
pooled data might not represent the general population.
In addition, the sample size was relatively small. Third, it
was not established whether any of the endoscopic BE
patients had a hiatus hernia, which is thought to be a
risk factor of BE development, as shown previously
[14,15,20]. Fourth, H. pylori infection, which appears to
have an inverse association with BE, was not evaluated
[40,51]. However, the present study showed that gastric
atrophy, which is caused by H. pylori infection, was not
related to BE development, a finding that is consistent
with the previous study [13]. Additionally, we did not
analyze the administration of nonsteroidal anti-
inflammatory drugs, including aspirin, which have been
significantly associated with a risk of BE [52].
Conclusions
In conclusion, simple and visceral obesity were not risk
factors for ESBE in the present study. In fact, RE was the
only one of the parameters studied that was a significant
risk factor for ESBE independent of obesity. Interest-
ingly, PPI-refractory RE and large WC in regular PPI
users were strongly associated with increasing risk of
ESBE ≥ 1 cm. Further studies with a larger sample size
will be needed to clarify the reason for this lack of asso-
ciation between obesity and ESBE in the Japanese
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